Shares of Fate Therapeutics Inc (NASDAQ:FATE) have been given an average recommendation of “Buy” by the nine research firms that are covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $7.67.
Several research firms have recently weighed in on FATE. ValuEngine upgraded Fate Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday. Zacks Investment Research downgraded Fate Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. BMO Capital Markets reiterated a “buy” rating and set a $7.00 price target on shares of Fate Therapeutics in a research note on Thursday, November 2nd. HC Wainwright reiterated a “buy” rating on shares of Fate Therapeutics in a research note on Thursday, November 2nd. Finally, Piper Jaffray Companies began coverage on Fate Therapeutics in a research note on Monday, December 18th. They set an “overweight” rating and a $10.00 price target for the company.
In related news, General Counsel Cindy Tahl sold 8,091 shares of the stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $3.85, for a total transaction of $31,150.35. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Daniel D. Shoemaker sold 13,225 shares of the stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $3.87, for a total value of $51,180.75. The disclosure for this sale can be found here. Corporate insiders own 10.88% of the company’s stock.
Fate Therapeutics (NASDAQ:FATE) opened at $6.50 on Thursday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 7.21 and a current ratio of 7.21. The firm has a market capitalization of $331.38, a price-to-earnings ratio of -6.84 and a beta of 1.52. Fate Therapeutics has a 12 month low of $2.44 and a 12 month high of $6.75.
Fate Therapeutics (NASDAQ:FATE) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.01). The firm had revenue of $1.03 million for the quarter, compared to the consensus estimate of $0.95 million. Fate Therapeutics had a negative return on equity of 64.55% and a negative net margin of 935.09%. The company’s revenue for the quarter was up .0% on a year-over-year basis. research analysts forecast that Fate Therapeutics will post -0.99 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Fate Therapeutics Inc (FATE) Receives Average Recommendation of “Buy” from Analysts” was reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/01/04/fate-therapeutics-inc-fate-receives-average-recommendation-of-buy-from-analysts.html.
About Fate Therapeutics
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.